At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 Study
In Brief
A Phase 4 clinical trial evaluating Live attenuated influenza vaccine and Surveillance (nasal swabbing) during influenza season for Influenza Vaccines Efficacy and Safety. Completed, enrolled 276 participants across 1 site.
Detailed Summary
The UK Departments of Health now recommend annual influenza vaccination for all children 2-7 years of age, with children over 7 years eligible for vaccination if in certain higher risk clinical categories. Though data are available documenting the safety and immunogenicity of LAIV in this age group, there are little data to assess efficacy and immune correlates in UK children, and in particular atopic children. This study will enrol 200 children (and at least 200 unvaccinated household sibling controls), many with a history of asthma or recurrent wheezing, and allow an assessment of efficacy, safety and immune correlates in these children, and how this varies with prior administration of pandemic influenza vaccine and/or LAIV.
Study Details
Timeline
Interventions
Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season